YBX-1 alleviates sepsis-stimulated lung epithelial cell injury
Allergol. immunopatol
; 52(2): 60-67, mar. 2024. ilus, graf
Artigo
em Inglês
| IBECS
| ID: ibc-231086
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Objective:
To explore the role of Y-box binding protein 1 (YBX-1) in the lipopolysaccharide (LPS)-stimulated inflammation and oxidative stress of BEAS-2B cell line and clarify the underlying mechanism.Methods:
LPS-stimulated BEAS-2B cells were used as a cell model of sepsis-stimulated acute lung injury (ALI). Immunoblot and quantitative polymerase chain reaction assays were used to detect the expression of YBX-1 in LPS-stimulated BEAS-2B cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, TdT-mediated dUTP nick end labeling, and immunoblot assays were conducted to determine the effects of YBX-1 on cell survival. JC-1 staining and adenosine triphosphate production were used to detect the effects of YBX-1 on mitochondrial function. Immunostaining and enzyme-linked immunosorbent serologic assay were performed to examine the effects of YBX-1 on the inflammation and oxidative stress of cells. Immunoblot assay was conducted to confirm the mechanism.Results:
YBX-1 was lowly expressed in LPS-stimulated BEAS-2B cells and enhanced the survival of LPS-stimulated lung epithelial cells. In addition, YBX-1 improved mitochondrial function of LPS-stimulated BEAS-2B cells. YBX-1 inhibited the inflammation and oxidative stress of LPS-stimulated BEAS-2B cells. Mechanically, YBX-1 inhibited mitogen-activated protein kinase (MAPK) axis, thereby alleviating sepsis-stimulated ALI.Conclusion:
YBX-1 alleviated inflammation and oxidative stress of LPS-stimulated BEAS-2B cells via MAPK axis. (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Sobrevivência Celular
/
Lipopolissacarídeos
/
Sepse
/
Proteína 1 de Ligação a Y-Box
/
Lesão Pulmonar Aguda
/
Células Epiteliais Alveolares
/
Inflamação
Limite:
Humanos
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2024
Tipo de documento:
Artigo
Instituição/País de afiliação:
the First Affiliated Hospital of Soochow University/China